|View printer-friendly version|
|Aptose Biosciences to Present at the 12th Annual BIO Asia International Conference|
APTO-253 represents an entirely new class of anticancer agents, which the Company believes may offer a competitive advantage over conventional drugs. APTO-253 is a small molecule optimized to induce the tumor suppressor Krüppel-like factor 4 (KLF4), leading to apoptotic death in cancer cells that have the KLF4 gene silenced. This drug candidate has shown selective and potent antitumor activity in preclinical investigations of certain human cancers, including solid and liquid tumors, and has demonstrated a robust safety profile and biological antitumor activity in a prior Phase 1 clinical trial in patients with solid tumors. APTO-253 is currently in a Phase 1b, multicenter, open-label, dose-escalation clinical trial in patients with relapsed or refractory hematologic malignancies.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such expressed or implied forward looking statements could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the
Aptose Biosciences: Greg Chow, CFO, 650-351-6716, email@example.com; BCC Partners: Karen L. Bergman or Susan Pietropaolo, 650-575-1509 or 845-638-6290, firstname.lastname@example.org or email@example.com